ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

EDEN Eden Research Plc

4.70
-0.35 (-6.93%)
12 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Eden Research Plc LSE:EDEN London Ordinary Share GB0001646941 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  -0.35 -6.93% 4.70 864,492 14:00:24
Bid Price Offer Price High Price Low Price Open Price
4.60 4.80 5.05 4.70 5.05
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Biological Pds,ex Diagnstics 1.83M -2.24M -0.0042 -11.90 26.67M
Last Trade Time Trade Type Trade Size Trade Price Currency
16:40:23 O 250,000 5.00 GBX

Eden Research (EDEN) Latest News

Eden Research (EDEN) Discussions and Chat

Eden Research Forums and Chat

Date Time Title Posts
11/4/202416:56Eden Research17,361
08/2/202407:42Eden....Onward and Upwards!52
21/6/202312:05The sterile garden of Eden123
29/3/202216:04Eden Research14
29/3/202214:36Eden Research - Who Is Behind Thallo Eco Products Corp?27

Add a New Thread

Eden Research (EDEN) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2024-04-12 15:40:255.00250,00012,500.00O
2024-04-12 15:36:545.00100,0005,000.00O
2024-04-12 13:22:384.75105,2904,996.01O
2024-04-12 13:00:344.6150,0002,305.00O
2024-04-12 13:00:254.7526,4431,256.02O

Eden Research (EDEN) Top Chat Posts

Top Posts
Posted at 12/4/2024 09:20 by Eden Research Daily Update
Eden Research Plc is listed in the Biological Pds,ex Diagnstics sector of the London Stock Exchange with ticker EDEN. The last closing price for Eden Research was 5.05p.
Eden Research currently has 533,352,523 shares in issue. The market capitalisation of Eden Research is £26,667,626.
Eden Research has a price to earnings ratio (PE ratio) of -11.90.
This morning EDEN shares opened at 5.05p
Posted at 22/3/2024 12:48 by investingisatrickygame
Super

'Corteva Catalyst'

I think we need a Share Price Catalyst!

California, the biggest state and entry point into the US market has provided no investor enthusiasm at all, both this side of the pond and US side.

Ecovelex EUA in Italy has provided no investor enthusiasm for this opportunity at all.

Will the forthcoming insecticide inspire the market to look at Eden through different eyes and if so, how?

What is going to put value into Eden's share price and in doing so, change the image of the Company in investing terms? And please don't anyone say sales. Every company needs sales and we all understand that, but plenty of listed companies pre-sales, have tremendous investor followings and share prices to match because the opportunity and scale is visible, there for all to see and investors have faith that it will or can in part be delivered.

Are investors lacking faith in Eden?

OR

Do investors not understand the value proposition in front of Eden?


Footnote: The Chairman spent £50,000 at 6p in the Placing of last summer, 2023

He understands the value proposition

Why does our long term career 'heavyweight' Chairman not step forward and be part of the investor communication from Eden and spell out the value proposition when investing in Eden today?

It is badly needed.
Posted at 08/3/2024 06:22 by supersonico
With the Insecticide I use the ITC2 Corteva model.

Eden are inside the big tent where different rules apply for the new #Make-Biologicals-Great era where the Gods of Ag (GOA) direct the show ..so inthecoming1 (ITC1) that applied to Mevalone and Cedroz do not closely correlate with Ecovelex where inthecoming2 (ITC2) has a date that is publicly expressed 3 years ahead of delivery.

The insecticide falls into the inthecoming2 big tent model where imo the GOA have been working with Eden since the #Celebrated Women of Syngenta ... Camilla Corsi and Smith shared a platform five years ago.

The terms and agreements between 'multiple interested parties' might well be more complicated but the progress has been steady and there has been plenty of time to talk terms since ITC1 evolved into the #collaboration ITC2 epoch.

AWAGATWT.

Annual Eden Insecticide / development update...2019- Jan 2024

15 January 2019;
The opportunities in Eden's core crop protection business are growing well. In addition to the products that Eden has developed and is commercialising through its partners, there are a number of pipeline products which are in the process of being tested by potential partners including several candidate insecticide products which would represent our first entry into the insecticide segment. Whilst it is early in the development of these formulations, initial results have been encouraging.


14 January 2020
Looking forward, we expect to be able to announce further marketing authorisations for both Mevalone and Cedroz as well as progress that is being made with existing and new partners in areas such as seed treatments, insecticides and other applications where the use of our active ingredients and Sustaineä encapsulation technology can bring important benefits to our commercial partners, growers, and ultimately consumers who benefit from sustainable agriculture."

11 February 2021
Development work continued largely as hoped during 2020, including on Eden's insecticide and seed treatment products. In addition, the Company continues to work with a number of parties to develop products that avoid polymer encapsulation using Eden's proprietary Sustaine® technology with third party active ingredients.

2nd March 2022
Development of Eden's seed treatment and insecticide products continues on track with good progress made in 2021 and the Corteva partnership has moved into the next stage of development triggering a milestone payment to Eden.


10 January 2023
Field trials in 2021 and 2022 have produced encouraging results for our insecticide candidates. The Company is pleased to be in position where it has now agreed on a final formulation, entered into testing agreements and sent trial-scale samples to multiple interested parties who are undertaking their own trial work.

Eden has started to see results from its potential partners come in and we are pleased to say that they are, thus far, in line with our own results.
The Company expects there to be a high level of interest for this product, particularly in the key markets of Europe and the US.

22 January 2024
A number of potential commercial partners for Eden's insecticide product ran, between them, a large number of field trials in 2023 and, so far, these have produced encouraging results.

Eden has started to see results from its potential partners come in and we are pleased to say that they are, thus far, in line with our own results.
The Company expects there to be a high level of interest for this product, particularly in the key markets of Europe and the US.

Eden has now started commercial discussions with various potential partners to begin the evaluation of who to appoint as distribution partner for the insecticide product and shall update the market during 2024, as appropriate.
................................................
Posted at 02/3/2024 11:19 by investingisatrickygame
Timbo_Slice

12p would give Eden a market cap of £64 million

Cavendish currently has a target price of 20p, so £107 million market cap

Eden talks about operating in $billion markets with Compound Annual Growth Rates of 15%+

It is not unreasonable for an investor to presume that Eden's target market cap is much higher than £107 million. That Cavendish number takes no account of the impending insecticide deal or its label extension (see Placing RNS) or the label extension(s) to Ecovelex or Powdery Mildew label extensions applied for on Mevalone, but not yet received e.g. France.

I believe Eden considers itself to be at the forefront or a leader in some of the work it is doing. That could be supported by, for example, Ecovelex and Corteva's recognition of the same.

Furthermore, Eden self-declares that it is "Our vision is to be a global leader in sustainable crop protection through the development of bioactive products enabled or enhanced by our novel encapsulation and delivery technologies."


You cannot make such statements and operate in $billion markets and be pleased with a £107 million market cap. That makes no sense on any level for a company in the process of 'global expansion'.

Given the above, Eden needs to sell this vision more directly to investors to mobilise the share price and get belief into the Company, visible in its share price, so that investors truly believe in the Company, their investment and that the value of their £1 today is near guaranteed to be worth significantly more in the near future.

If not, we need to talk about being a participant in £million markets and reset both ambition and expectation.

I'm pretty sure the former statement sits better and more accurately, so Eden needs to communicate this more effectively so it it properly understood and so that such commentary and written words are not throw away, meaningless statements.
Posted at 24/2/2024 16:01 by investingisatrickygame
Information Post

Cavendish price target 20p
Eden share price below 6p
Upside 300%+++

As KittyBiscuits say's, just an information post :)
Posted at 14/2/2024 09:01 by investingisatrickygame
Hi Super,

if you are referring to the podcast US conference, not really. Like AttyG, who can speak for themself, and comment here again if they wish too, I think Eden is likely understating numbers. I will give 2 examples

1) In the US Podcast & slide presentation Alex Abrey sited the Ecovelex opportunity as €35-40 million globally. However, in the 2020 Placing, Subscription and Open Offer RNS, Eden states the Ecovelex opportunity as €40 million from 'European geographies alone. At that point in time it was referred to 'this product' and not named as Ecovelex.

2) In the same presentation, they say the insecticide opportunity has the same €35-40 million opportunity globally. However, on Eden's website they state that the insecticide has a 5%-10% opportunity of an €850 million market from the US and Europe alone Source:

So for me, the numbers and the geographies don't align. Even allowing for addressable markets changing, their is a huge different from 'European geographies alone' and globally. Similarly with the insecticide.

It only serves to confuse understanding of what the opportunity is.

So questions

What is the European Ecovelex maize opportunity?
What is the US Ecovelex maize opportunity?
What is the ROW Ecovelex maize opportunity?

Then to suggest what might be as Corteva has put it in the public domain

What is the European Ecovelex Sunflower opportunity that Corteva is evaluating?
Similarly with the US and the ROW.

It is a case of setting the scene of what might be. No one is going to get excited about.

2023 AGM Presentation

When you look at the numbers on slides 3 & 5 and then look at 'current' € value prospects by product, they are totally disconnected. For me at least, they are.

Might it be better with Mevalone, for instance, to say that the addressable market for fungicides treating grapes (Eden's current primary target for Mevalone) is X and then show Eden's target sales against this. Isn't this a more realistic measure of what Eden is seeking to achieve.

The global biopesticide market may be worth $11 billion by 2027 growing at 15% CAGR as detailed on slide 5, but that has no real world correlation to Eden, their prospects and investor expectations. Eden for a while has been talking global market $billions, but that is not the world we are in.

We recently did a video interview entitled 'global expansion', but we didn't, in my view, excite investors about what that global expansion looks like and why you should invest in Eden. No NDA is going to restrict that story being told. When you IPO, you tell investors why they should place their money in your company. Well for me, that is an ongoing journey of telling investors why they should invest in your company. It doesn't stop post listing.

I think there is a lot for Eden to review about how they woo investors in order to realise the share price they and we believe we deserve.
Posted at 14/2/2024 07:01 by investingisatrickygame
"Only sales/profits will bring the share price up"

I'd have to respectfully disagree. Many a loss making company has seen a dramatic and sustained rise in their share price because the company has talked about the forward prospects and the market has been excited by those prospects. Inevitably they can trade on ridiculous, to you and me, P/E ratios, but they do so because the market is excited by their prospects and believes in them. The market then invests their hard earned $/£/€ and the share price reacts in a positive way.

Ultimately, they do have to achieve what they say, but saying it in a certain way does allow the share price to move upwards. This is usually true of companies with global opportunities and Eden has global opportunities. It matters not whether they operate in a regulated market or not.

Super,

Many companies will be bound by NDA's for all kinds of things. Eden is not unique in this position and it doesn't prevent them talking Eden's prospects up where it is justified. I for one, simply don't believe we have gone to the effort of regulatory approvals post years of trials in what is currently 19 countries for the market to believe that footprint is worth just £30 million. That is a ridiculous valuation for addressing global agricultural problems and when Eden references $billion+ markets with the biopesticide market experiencing 15%+ CAGR.

I choose to believe that Eden's know-how around what they do with terpenes is worth more than £30 million alone. To quote our chairman " I am used to seeing one molecule do one thing in my career, but with Eden, one molecule can do many things".



Member of the Board of Management of Bayer Cropscience

Head of Bayer Cropscience Bioscience division

You don't hold such (relevant to Eden) career positions, make a statement such as that and based on such long-term insight and believe your company is worth just £30 million. The share price is completely and utterly disconnected from where it should be and the company needs to do something about it. Cavendish needs to help them too. Hawthorn needs to try harder.
Posted at 12/2/2024 21:06 by investingisatrickygame
Eden has done a series of PR/IR exercises for a US audience now and it would appear to me, no takers thus far. I haven't seen a volume change to suggest so. That said, the pragmatic amongst us accept that it takes time. Even so, allowing for those events, there has been enough time for some to come into the market and buy stock.

The share price sits at 5.625p showing a MCap of circa £30 million which would be even less, but for the recent increase in the number of shares in issue following a capital raise.

'Our' share price has made NO progress in the last 5+ years, yet the Company has increased regulatory approvals, label extensions & NPD such as Ecovelex.

There is one known major announcement left to come and it is our insecticide. Treating 4 insects as opposed to the standard 2, we wait to see if we will deal with one global partner or several partners. After this announcement, there is no known new products to be announced and the known future is regulatory approvals, as and when and label extensions, as and when. Even if there are new products, they will be and revenue will be a minimum 3 years away which Eden has stated itself.

So if the insecticide announcement doesn't substantially move our share price, what will and when?

To me, the insecticide is a pivotal moment. If Eden doesn't grab the attention of the investment community with that announcement and the share price doesn't factor in future income and possibilities then to me, others may well disagree, Eden looks vulnerable.

Others with deeper pockets may well see that those pockets are better able to more quickly deliver revenue in a sustainable way that perhaps, Eden cannot. For all of Eden's ingenuity and know how, as a public company, they have to satisfy the investment community & shareholders and a continued inability to do that, as evidenced by the share price, can surely only lead to one outcome.

We can't talk about global expansion, 19 countries, some products that have been available for years, but with revenue subject to weather (an unknown every year and difficult if not impossible to financially forecast) and at the same time talk about $billion markets without penetration in any meaningful way.

Either we have the capability now to sell tens of $millions of product as AttyG has suggested, or we don't. If we do, then the investment proposition has to be sold more appropriately, more aggressively, such that it is sufficiently realised to create investment momentum, something I am not sure I have ever seen in Eden.
Posted at 24/1/2024 17:42 by supersonico
Annual Eden Insecticide / development update...2019- Jan 2024

15 January 2019;
The opportunities in Eden's core crop protection business are growing well. In addition to the products that Eden has developed and is commercialising through its partners, there are a number of pipeline products which are in the process of being tested by potential partners including several candidate insecticide products which would represent our first entry into the insecticide segment. Whilst it is early in the development of these formulations, initial results have been encouraging.


14 January 2020
Looking forward, we expect to be able to announce further marketing authorisations for both Mevalone and Cedroz as well as progress that is being made with existing and new partners in areas such as seed treatments, insecticides and other applications where the use of our active ingredients and Sustaineä encapsulation technology can bring important benefits to our commercial partners, growers, and ultimately consumers who benefit from sustainable agriculture."

11 February 2021
Development work continued largely as hoped during 2020, including on Eden's insecticide and seed treatment products. In addition, the Company continues to work with a number of parties to develop products that avoid polymer encapsulation using Eden's proprietary Sustaine® technology with third party active ingredients.

2nd March 2022
Development of Eden's seed treatment and insecticide products continues on track with good progress made in 2021 and the Corteva partnership has moved into the next stage of development triggering a milestone payment to Eden.


10 January 2023
Field trials in 2021 and 2022 have produced encouraging results for our insecticide candidates. The Company is pleased to be in position where it has now agreed on a final formulation, entered into testing agreements and sent trial-scale samples to multiple interested parties who are undertaking their own trial work.

Eden has started to see results from its potential partners come in and we are pleased to say that they are, thus far, in line with our own results.
The Company expects there to be a high level of interest for this product, particularly in the key markets of Europe and the US.

22 January 2024
A number of potential commercial partners for Eden's insecticide product ran, between them, a large number of field trials in 2023 and, so far, these have produced encouraging results.

Eden has started to see results from its potential partners come in and we are pleased to say that they are, thus far, in line with our own results.
The Company expects there to be a high level of interest for this product, particularly in the key markets of Europe and the US.

Eden has now started commercial discussions with various potential partners to begin the evaluation of who to appoint as distribution partner for the insecticide product and shall update the market during 2024, as appropriate.
................................................

30 November 2023

Abrey commentary from ..Presentation from the November 30 Small Cap Growth Virtual Investor Conference

"We have undertaken a large number of field trials ourselves, this year we had Partners ..potential partners undertaking their own trials in excess of 140 in total spread across the potential partners so we hope and expect by the end of this year to have all the results from those various trials that have been undertaken and early indications are positive.

We will then move into commercial negotiations with those potential partners ..we would look to do distribution agreements with some or maybe one or all of those potential partners and it could be it's a global deal or a regional or even country by country ..it remains to be seen and depends on the business cases put forward to us ..but this one we're really excited about ..it's a big opportunity ..there is a dearth of Bio-insecticides available which is why we have seen so much interest for this product ..in terms of the actual opportunity again this is a big one for us potentially around $35-$40m per annum at peak".

(Eden Research plc (OTCQB: EDNSF | AIM: EDEN): Virtual Investor Conferences /
Posted at 23/1/2024 12:19 by monet
Neuts OBSESSION with EDEN 24/7,Neuts OBSESSION with EDEN 24/7,Neuts OBSESSION with EDEN 24/7,Neuts OBSESSION with EDEN 24/7,Neuts OBSESSION with EDEN 24/7,Neuts OBSESSION with EDEN 24/7,Neuts OBSESSION with EDEN 24/7,Neuts OBSESSION with EDEN 24/7,Neuts OBSESSION with EDEN 24/7,Neuts OBSESSION with EDEN 24/7,Neuts OBSESSION with EDEN 24/7,Neuts OBSESSION with EDEN 24/7,Neuts OBSESSION with EDEN 24/7,Neuts OBSESSION with EDEN 24/7,Neuts OBSESSION with EDEN 24/7,Neuts OBSESSION with EDEN 24/7,Neuts OBSESSION with EDEN 24/7,Neuts OBSESSION with EDEN 24/7,Neuts OBSESSION with EDEN 24/7,Neuts OBSESSION with EDEN 24/7,Neuts OBSESSION with EDEN 24/7,Neuts OBSESSION with EDEN 24/7,Neuts OBSESSION with EDEN 24/7,Neuts OBSESSION with EDEN 24/7,Neuts OBSESSION with EDEN 24/7,Neuts OBSESSION with EDEN 24/7,Neuts OBSESSION with EDEN 24/7,Neuts OBSESSION with EDEN 24/7,Neuts OBSESSION with EDEN 24/7,Neuts OBSESSION with EDEN 24/7,Neuts OBSESSION with EDEN 24/7,Neuts OBSESSION with EDEN 24/7,Neuts OBSESSION with EDEN 24/7,Neuts OBSESSION with EDEN 24/7,Neuts OBSESSION with EDEN 24/7,Neuts OBSESSION with EDEN 24/7,Neuts OBSESSION with EDEN 24/7,Neuts OBSESSION with EDEN 24/7,Neuts OBSESSION with EDEN 24/7,Neuts OBSESSION with EDEN 24/7,
Posted at 22/1/2024 06:38 by supersonico
NUMBER OF AIM SECURITIES IN ISSUE
As of 3 January 2024, the number of shares in issue was 533,352,523.

SIGNIFICANT SHAREHOLDERS
As of 3 January 2024 significant shareholdings in the share capital of Eden Research plc were:

Name

Number of shares

% of the issued ordinary share capital

Hargreaves Lansdown
53,364,313
10.01%

Gresham House Asset Management Limited
52,882,786
9.92%

Octopus Investments
41,551,047
7.79%

Sipcam Oxon S.p.A.
39,285,138
7.37%

Interactive Investor
33,363,457
6.26%

Canaccord Genuity Wealth Management
30,276,307
5.68%

Unicorn Asset Management
23,076,923
4.33%

Rathbones
23,040,287
4.32%

Atul Unadkat
22,099,924
4.14%

JM Finn Nominees Limited
20,147,562
3.78%

Amati Global Investors
16,744,070
3.14%

BGF Investment Management Limited
16,000,576
3.00%

............................

As of 20 July 2023, the number of shares in issue was 381,108,607.

SIGNIFICANT SHAREHOLDERS
As of 20 July 2023 significant shareholdings in the share capital of Eden Research plc were:

Name
Number of shares
% of the issued ordinary share capital

Hargreaves Lansdown
45,307,219
11.89%

Sipcam Oxon S.p.A.
37,614,830
9.87%

Interactive Investor
31,957,945
8.39%

Gresham House Asset Management Limited
27,845,445
7.31%

Canaccord Genuity Group Inc
22,584,000
5.93%

BGF Investment Management Limited
20,233,000
5.31%

JM Finn Nominees Limited
19,635,562
5.15%

Atul Unadkat
18,811,765
4.94%

Rathbone Nominees Limited
13,661,661
3.58%

HSBC Global Custody Nominee (UK) Limited
13,066,384
3.43%

HSDL Stockbrokers
12,436,733
3.26%


Name
Number of shares
% of the issued ordinary share capital

A Abrey
1,620,346
0.43%

L van der Broek
929,500
0.24%

S Smith
911,039
0.24%

R Cridland
130,167
0.03%
...................

NUMBER OF AIM SECURITIES IN ISSUE
As of 21 March 2023, the number of shares in issue was 380,858,607.

SIGNIFICANT SHAREHOLDERS
As of 21 March 2023 significant shareholdings in the share capital of Eden Research plc were:


Name

Number of shares

% of the issued ordinary share capital

BGF Investment Management Limited
51,733,000
13.58%

Sipcam Oxon S.p.A.
37,614,830
9.88%

Hargreaves Lansdown
31,737,596
8.33%

Gresham House Asset Management Limited
27,845,445
7.31%


Interactive Investor
25,172,555
6.61%

Canaccord Genuity Group Inc
22,584,000
5.93%

JM Finn Nominees Limited
19,839,762
5.21%

Atul Unadkat
18,117,567
4.76%

Rathbone Nominees Limited
15,621,872
4.10%

HSBC Global Custody Nominee (UK) Limited
13,066,384
3.43%



Name
Number of shares
% of the issued ordinary share capital

A Abrey
1,620,346
0.43%

L van der Broek
929,500
0.24%

S Smith
911,039
0.24%

R Cridland
130,167
0.03%


SHARES NOT IN PUBLIC HANDS
In the terms of AIM Rules published July 2016 and insofar as it is aware, at 21 March 2023, 31.71% of the Company's AIM securities was not in public hands.

.................................................................................

Atul keeps buying.

As of 30 September 2022, the number of shares in issue was 380,858,607.
As of 30 September 2022, significant shareholdings in the share capital of Eden Research plc were:

Number of shares % of the issued ordinary share capital

BGF Investment Management Limited
53,733,000
14.11%

Sipcam Oxon S.p.A.
37,614,830
9.88%

Hargreaves Lansdown
29,839,285
7.83%

Gresham House Asset Management Limited
27,845,445
7.31%


Canaccord Genuity Group Inc
22,584,000
5.93%

Interactive Investor
20,027,730
5.26%

JM Finn Nominees Limited
19,277,362
5.06%

Atul Unadkat
17,545,098
4.61%

Rathbone Nominees Limited
15,708,999
4.12%

HSBC Global Custody Nominee (UK) Limited
13,270,588
3.48%


......................................................................................................................

NUMBER OF AIM SECURITIES IN ISSUE
As of 09 March 2022, the number of shares in issue was 380,340,229.

SIGNIFICANT SHAREHOLDERS
As of 09 March 2022, significant shareholdings in the share capital of Eden Research plc were:

Name
Number of shares
% of the issued ordinary share capital

BGF Investment Management Limited
54,933,000
14.44%

Sipcam Oxon S.p.A.
37,614,830
9.89%

Gresham House Asset Management Limited
27,845,445
7.32%

Hargreaves Lansdown
25,331,396
6.66%


Canaccord Genuity Group Inc
22,584,000
5.94%

JM Finn Nominees Limited
20,386,275
5.36%

Interactive Investor
19,790,573
5.20%

Atul Unadkat
17,350,145
4.38%

Rathbone Nominees Limited
16,095,276
4.24%

Amati AIM VCT plc
14,282,652
3.76%

HSBC Global Custody Nominee (UK) Limited
13,270,588
3.49%



.....................................
NUMBER OF AIM SECURITIES IN ISSUE
As of 18 August 2021, the number of shares in issue was 380,340,229.

SIGNIFICANT SHAREHOLDERS
As of 18 August 2021, significant shareholdings in the share capital of Eden Research plc were:


Name
Number of shares
% of the issued ordinary share capital

BGF Investment Management Limited
54,933,000
14.44%

Sipcam Oxon S.p.A.
37,614,830
9.89%

Gresham House Asset Management Limited
27,845,445
7.32%

Hargreaves Lansdown
25,331,396
6.66%


Canaccord Genuity Group Inc
22,584,000
5.94%

JM Finn Nominees Limited
20,386,275
5.36%

Interactive Investor
19,790,573
5.20%

Rathbone Nominees Limited
16,122,338
4.24%

Amati AIM VCT plc
14,282,652
3.76%

HSBC Global Custody Nominee (UK) Limited
13,270,588
3.49%

...................


Home
SECURITIES INFORMATION


NUMBER OF AIM SECURITIES IN ISSUE
As of 21 February 2021, the number of shares in issue was 380,340,229.

SIGNIFICANT SHAREHOLDERS
As of 21 February 2021, significant shareholdings in the share capital of Eden Research plc were:


Name
Number of shares
% of the issued ordinary share capital

BGF Investment Management Limited
58,333,000
15.34%

Sipcam Oxon S.p.A.
37,614,830
9.89%

Gresham House Asset Management Limited
27,845,445
7.32%

Hargreaves Lansdown
25,452,709
6.69%


Canaccord Genuity Group Inc
22,584,000
5.94%

JM Finn Nominees Limited
20,421,575
5.37%

Amati AIM VCT plc
16,937,750
4.45%

Rathbone Nominees Limited
16,156,166
4.25%

Interactive Investor
15,405,978
4.05%

HSBC Global Custody Nominee (UK) Limited
14,015,588
3.69%


NUMBER OF AIM SECURITIES IN ISSUE
As of 21 August 2020, the number of shares in issue was 380,340,229.

SIGNIFICANT SHAREHOLDERS
As of 21 August 2020, significant shareholdings in the share capital of Eden Research plc were:


BGF Investment Management Limited
58,333,000
15.34%

Sipcam Oxon S.p.A.
37,614,830
9.89%

Hargreaves Lansdown
30,276,493
7.96%

Gresham House Asset Management Limited
27,845,445
7.32%

Canaccord Genuity Group Inc
22,684,000
5.94%

JM Finn Nominees Limited
21,774,435
5.72%

Amati AIM VCT plc
16,937,750
4.45%

Rathbone Nominees Limited
16,246,373
4.27%

HSBC Global Custody Nominee (UK) Limited
14,007,734
3.68%

Interactive Investor
12,992,073
3.42%


supersonico - 03 Dec 2022 - 07:03:11 - 13502 of 14935 Eden Research - EDEN
Atul keeps buying.

As of 30 September 2022, the number of shares in issue was 380,858,607.
As of 30 September 2022, significant shareholdings in the share capital of Eden Research plc were:

Number of shares % of the issued ordinary share capital

BGF Investment Management Limited
53,733,000
14.11%

Sipcam Oxon S.p.A.
37,614,830
9.88%

Hargreaves Lansdown
29,839,285
7.83%

Gresham House Asset Management Limited
27,845,445
7.31%


Canaccord Genuity Group Inc
22,584,000
5.93%

Interactive Investor
20,027,730
5.26%

JM Finn Nominees Limited
19,277,362
5.06%

Atul Unadkat
17,545,098
4.61%

Rathbone Nominees Limited
15,708,999
4.12%

HSBC Global Custody Nominee (UK) Limited
13,270,588
3.48%


......................................................................................................................

NUMBER OF AIM SECURITIES IN ISSUE
As of 09 March 2022, the number of shares in issue was 380,340,229.

SIGNIFICANT SHAREHOLDERS
As of 09 March 2022, significant shareholdings in the share capital of Eden Research plc were:

Name
Number of shares
% of the issued ordinary share capital

BGF Investment Management Limited
54,933,000
14.44%

Sipcam Oxon S.p.A.
37,614,830
9.89%

Gresham House Asset Management Limited
27,845,445
7.32%

Hargreaves Lansdown
25,331,396
6.66%


Canaccord Genuity Group Inc
22,584,000
5.94%

JM Finn Nominees Limited
20,386,275
5.36%

Interactive Investor
19,790,573
5.20%

Atul Unadkat
17,350,145
4.38%

Rathbone Nominees Limited
16,095,276
4.24%

Amati AIM VCT plc
14,282,652
3.76%

HSBC Global Custody Nominee (UK) Limited
13,270,588
3.49%



.....................................
NUMBER OF AIM SECURITIES IN ISSUE
As of 18 August 2021, the number of shares in issue was 380,340,229.

SIGNIFICANT SHAREHOLDERS
As of 18 August 2021, significant shareholdings in the share capital of Eden Research plc were:


Name
Number of shares
% of the issued ordinary share capital

BGF Investment Management Limited
54,933,000
14.44%

Sipcam Oxon S.p.A.
37,614,830
9.89%

Gresham House Asset Management Limited
27,845,445
7.32%

Hargreaves Lansdown
25,331,396
6.66%


Canaccord Genuity Group Inc
22,584,000
5.94%

JM Finn Nominees Limited
20,386,275
5.36%

Interactive Investor
19,790,573
5.20%

Rathbone Nominees Limited
16,122,338
4.24%

Amati AIM VCT plc
14,282,652
3.76%

HSBC Global Custody Nominee (UK) Limited
13,270,588
3.49%

...................


Home
SECURITIES INFORMATION


NUMBER OF AIM SECURITIES IN ISSUE
As of 21 February 2021, the number of shares in issue was 380,340,229.

SIGNIFICANT SHAREHOLDERS
As of 21 February 2021, significant shareholdings in the share capital of Eden Research plc were:


Name
Number of shares
% of the issued ordinary share capital

BGF Investment Management Limited
58,333,000
15.34%

Sipcam Oxon S.p.A.
37,614,830
9.89%

Gresham House Asset Management Limited
27,845,445
7.32%

Hargreaves Lansdown
25,452,709
6.69%


Canaccord Genuity Group Inc
22,584,000
5.94%

JM Finn Nominees Limited
20,421,575
5.37%

Amati AIM VCT plc
16,937,750
4.45%

Rathbone Nominees Limited
16,156,166
4.25%

Interactive Investor
15,405,978
4.05%

HSBC Global Custody Nominee (UK) Limited
14,015,588
3.69%


NUMBER OF AIM SECURITIES IN ISSUE
As of 21 August 2020, the number of shares in issue was 380,340,229.

SIGNIFICANT SHAREHOLDERS
As of 21 August 2020, significant shareholdings in the share capital of Eden Research plc were:


BGF Investment Management Limited
58,333,000
15.34%

Sipcam Oxon S.p.A.
37,614,830
9.89%

Hargreaves Lansdown
30,276,493
7.96%

Gresham House Asset Management Limited
27,845,445
7.32%

Canaccord Genuity Group Inc
22,684,000
5.94%

JM Finn Nominees Limited
21,774,435
5.72%

Amati AIM VCT plc
16,937,750
4.45%

Rathbone Nominees Limited
16,246,373
4.27%

HSBC Global Custody Nominee (UK) Limited
14,007,734
3.68%

Interactive Investor
12,992,073
3.42%


supersonico - 05 Oct 2022 - 08:52:18 - 13219 of 14935 Eden Research - EDEN
Selling yes..but it's a dribble which has been bought by Atul etal.

As of 30 September 2022, the number of shares in issue was 380,858,607.
As of 30 September 2022, significant shareholdings in the share capital of Eden Research plc were:

Number of shares % of the issued ordinary share capital

BGF Investment Management Limited
53,733,000
14.11%

Sipcam Oxon S.p.A.
37,614,830
9.88%

Hargreaves Lansdown
29,839,285
7.83%

Gresham House Asset Management Limited
27,845,445
7.31%


Canaccord Genuity Group Inc
22,584,000
5.93%

Interactive Investor
20,027,730
5.26%

JM Finn Nominees Limited
19,277,362
5.06%

Atul Unadkat
17,545,098
4.61%

Rathbone Nominees Limited
15,708,999
4.12%

HSBC Global Custody Nominee (UK) Limited
13,270,588
3.48%


......................................................................................................................

NUMBER OF AIM SECURITIES IN ISSUE
As of 09 March 2022, the number of shares in issue was 380,340,229.

SIGNIFICANT SHAREHOLDERS
As of 09 March 2022, significant shareholdings in the share capital of Eden Research plc were:

Name
Number of shares
% of the issued ordinary share capital

BGF Investment Management Limited
54,933,000
14.44%

Sipcam Oxon S.p.A.
37,614,830
9.89%

Gresham House Asset Management Limited
27,845,445
7.32%

Hargreaves Lansdown
25,331,396
6.66%


Canaccord Genuity Group Inc
22,584,000
5.94%

JM Finn Nominees Limited
20,386,275
5.36%

Interactive Investor
19,790,573
5.20%

Atul Unadkat
17,350,145
4.38%

Rathbone Nominees Limited
16,095,276
4.24%

Amati AIM VCT plc
14,282,652
3.76%

HSBC Global Custody Nominee (UK) Limited
13,270,588
3.49%



.....................................
NUMBER OF AIM SECURITIES IN ISSUE
As of 18 August 2021, the number of shares in issue was 380,340,229.

SIGNIFICANT SHAREHOLDERS
As of 18 August 2021, significant shareholdings in the share capital of Eden Research plc were:


Name
Number of shares
% of the issued ordinary share capital

BGF Investment Management Limited
54,933,000
14.44%

Sipcam Oxon S.p.A.
37,614,830
9.89%

Gresham House Asset Management Limited
27,845,445
7.32%

Hargreaves Lansdown
25,331,396
6.66%


Canaccord Genuity Group Inc
22,584,000
5.94%

JM Finn Nominees Limited
20,386,275
5.36%

Interactive Investor
19,790,573
5.20%

Rathbone Nominees Limited
16,122,338
4.24%

Amati AIM VCT plc
14,282,652
3.76%

HSBC Global Custody Nominee (UK) Limited
13,270,588
3.49%

...................


Home
SECURITIES INFORMATION


NUMBER OF AIM SECURITIES IN ISSUE
As of 21 February 2021, the number of shares in issue was 380,340,229.

SIGNIFICANT SHAREHOLDERS
As of 21 February 2021, significant shareholdings in the share capital of Eden Research plc were:


Name
Number of shares
% of the issued ordinary share capital

BGF Investment Management Limited
58,333,000
15.34%

Sipcam Oxon S.p.A.
37,614,830
9.89%

Gresham House Asset Management Limited
27,845,445
7.32%

Hargreaves Lansdown
25,452,709
6.69%


Canaccord Genuity Group Inc
22,584,000
5.94%

JM Finn Nominees Limited
20,421,575
5.37%

Amati AIM VCT plc
16,937,750
4.45%

Rathbone Nominees Limited
16,156,166
4.25%

Interactive Investor
15,405,978
4.05%

HSBC Global Custody Nominee (UK) Limited
14,015,588
3.69%


NUMBER OF AIM SECURITIES IN ISSUE
As of 21 August 2020, the number of shares in issue was 380,340,229.

SIGNIFICANT SHAREHOLDERS
As of 21 August 2020, significant shareholdings in the share capital of Eden Research plc were:


BGF Investment Management Limited
58,333,000
15.34%

Sipcam Oxon S.p.A.
37,614,830
9.89%

Hargreaves Lansdown
30,276,493
7.96%

Gresham House Asset Management Limited
27,845,445
7.32%

Canaccord Genuity Group Inc
22,684,000
5.94%

JM Finn Nominees Limited
21,774,435
5.72%

Amati AIM VCT plc
16,937,750
4.45%

Rathbone Nominees Limited
16,246,373
4.27%

HSBC Global Custody Nominee (UK) Limited
14,007,734
3.68%

Interactive Investor
12,992,073
3.42%


1
Eden Research share price data is direct from the London Stock Exchange

Your Recent History

Delayed Upgrade Clock